COMMUNIQUÉS West-GlobeNewswire

NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2
10/03/2026
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a clinical-stage biotechnology [...]
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
10/03/2026
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and [...]
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
10/03/2026
Kane also signs U.S.-based contract sales agents WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health [...]
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
10/03/2026
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
10/03/2026
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients [...]
Piston Bio Announces FDA Alignment on PST-101 Development Program for Cancer-Related Apathy
10/03/2026
MORRISTOWN, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Piston Bio LLC, a clinical-stage biotechnology company developing therapeutics targeting neuroimmune mechanisms in cancer, today announced the completion of a Type B [...]
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
10/03/2026
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB [...]
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Reported record total revenue of $19.2 million in the fourth quarter of 2025 Scaling U.S. commercial launch of AYON Body Contouring System ™ (AYON) to meet strong market demand Expect FY2026 total revenue in the range [...]
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
10/03/2026
PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
10/03/2026
- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics architecture delivers [...]
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
10/03/2026
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced [...]
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
10/03/2026
BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit organizations, including [...]
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
10/03/2026
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric [...]
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
10/03/2026
EDAP to Present at Oppenheimer 36 th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18 th , 2026 AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA ( [...]
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
10/03/2026
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug [...]
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
10/03/2026
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to [...]
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
10/03/2026
GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase [...]
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
10/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 10 MARCH 2026 at 13.50 EET Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026 In accordance with a decision by the Board of [...]
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10/03/2026
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy [...]

Pages